USPTO serial 79281970
INPHARMA RESEARCH · DEVELOP PRODUCE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 8, 2021
- Examiner
- VAN DEN ABEELEN, DEREK C
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with INPHARMA RESEARCH · DEVELOP PRODUCE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Francesco Braga
Francesco Braga Perani & Partners S.p.A.Piazza Armando Diaz 7Milano MI, 20123ITALYGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Foodstuffs and dietetic substances for medical and veterinary purposes, namely, dietary supplements, food grade products being capsules sold empty for pharmaceuticals, infant food for medical purposes, Organic food supplements, organic dietary supplements, powder food supplements, liquid food supplements, dietary supplements that are sold in a container cap for subsequent delivery into liquids, newborn food supplements, infant food supplements, wellness dietary supplements, natural dietary supplements for the treatment of the mental health, nutritionally complete dietetic foods with a standard nutrient formulation adapted for medical purposes, nutritionally complete dietetic foods with a nutrient-adapted formulation specific for a disease, nutritionally incomplete dietetic foods with a standard formulation or a nutrient-adapted formulation specific for a disease; dietetic and nutritional preparations for medical use; infant formula; dietetic substances for babies for medical purposes; dietary supplements for infants; dietary supplements for humans and animals; food supplements; dietary food supplements, not for medical purposes; dietary supplements; nutritional supplements; dietary supplement drink mixes; dietary supplemental drinks; dietetic beverages adapted for medical purposes; multi-vitamin preparations; vitamins and vitamin preparations; dietary supplements for athletes; powdered nutritional supplement drink mix; dietetic foodstuffs for medical purposes, namely, dietary supplements; probiotic supplements; prebiotic supplements; probiotic bacterial formulations for medical use, namely, probiotic supplements; probiotic preparations for medical use to help maintain a natural balance of flora in the digestive system; milk ferments for pharmaceutical purposes; pharmaceutical preparations and substances for treating constipation or diarrhoea; pharmaceutical preparations and substances, namely, Antioxidants, nutritional supplements for boosting energy, Multivitamins, Sleeping pills/tablets, Immunostimulants, oral Rehydration salts, Vitamins, skin Enhancers being medicated skin care preparations, Nasal sprays, Amino acids, Antiemetic preparations, nutritional supplements consisting primarily of iron, Anti-inflammatories, lozenges to relieve sore throat, cough syrups, anti-obesity diet capsules; medicinal preparations and substances for treating constipation or diarrhoea; medicinal preparations and substances, namely, nutritional supplements for boosting energy, Multivitamins, Sleeping pills/tablets, Immunostimulants, oral Rehydration salts, Vitamins, skin Enhancers being medicated skin care preparations, Nasal sprays, Amino acids, Antiemetic preparations, nutritional supplements consisting primarily of iron, Anti-inflammatories, lozenges to relieve sore throat, cough syrups, anti-obesity diet capsules; antibacterial substances for medical purposes; diagnostic substances for medical use; astringents for medical purposes; pharmaceutical antiallergic preparations and substances; bactericides; medical devices based on substances, namely, delivery agents in the form of dissolvable films that facilitate the delivery of nutritional supplements, nasal sprays for cold symptoms, sprays to relieve sore throat | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 8, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Apr 30, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 24, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 28, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 27, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 8, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 8, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 23, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 23, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 21, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Mar 3, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 3, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 3, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 18, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 18, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 18, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 18, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 18, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 9, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 9, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 6, 2021 | ALIE | ASSIGNED TO LIE | — |
| Nov 3, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 23, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 3, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 3, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 22, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 21, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 4, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 31, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 31, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 26, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |